logo-loader

hVIVO PLC

Receive alerts
Market:
LSE
Market Cap:
£13.73 m
Price
16.50 GBX
Change
0.00%
52 weeks high
55.55
52 weeks low
13.20

In brief

Established in 1989 as a spin out from Queen Mary University, London, hVIVO is a trusted partner and industry-leading clinical development services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious disease.

hVIVO conducts studies and provides services for customers, both pharmaceutical and biotech companies, utilising a range of different client trial and laboratory methodologies across differing viral challenges. Experience and know-how from over 50 challenge studies is applied to ensure effective study design and excellent service delivery for customers.

Deep dive We explore the investor case for growth companies

Snapshot

The challenge trial charts the entire disease life cycle from healthy to sick and back to health.